What is the appropriate oral acyclovir dosing regimen for treating herpes labialis in a healthy adult, including dosing for children, patients with renal impairment, and short‑term suppressive therapy?

Acyclovir Dosing for Cold Sores (Herpes Labialis)

For episodic treatment of cold sores in healthy adults, use acyclovir 800 mg orally twice daily for 5 days, initiated during the prodrome or within 24 hours of lesion onset. 1

Standard Episodic Treatment Regimens

The CDC provides three equally effective oral acyclovir options for treating recurrent cold sores, all for 5 days: 1

• Acyclovir 800 mg twice daily (most convenient, best adherence) 1
• Acyclovir 400 mg three times daily 1, 2
• Acyclovir 200 mg five times daily (least convenient, poorest adherence) 1, 3

The 800 mg twice-daily regimen is preferred because it offers equivalent efficacy with superior convenience, reducing symptom duration from 12.5 to 8.1 days and pain duration from 3.9 to 2.5 days compared to placebo. 1

Critical Timing Considerations

Treatment must be initiated during the prodrome (tingling, burning) or within 24 hours of lesion appearance to achieve maximum benefit, as peak viral titers occur in the first 24 hours. 1, 4 Starting therapy after this window significantly reduces effectiveness. 1, 4

Pediatric Dosing

For children with cold sores or gingivostomatitis: 2

• Mild oral HSV (children <45 kg): Acyclovir 20 mg/kg orally three times daily (maximum 400 mg/dose) for 5–10 days 4, 2
• Moderate to severe gingivostomatitis requiring hospitalization: Start acyclovir 5–10 mg/kg IV every 8 hours until lesions regress, then switch to oral therapy and continue until complete healing 4, 2

Suppressive Therapy for Frequent Recurrences

For patients with ≥6 cold sore episodes per year, use acyclovir 400 mg orally twice daily for chronic suppression. 4, 2 This regimen reduces recurrence frequency by ≥75%. 4, 2

Suppressive Therapy Details

• Efficacy: Extends median time to first recurrence from 46 days (placebo) to 118 days, with a 53% reduction in clinical recurrences and 71% reduction in culture-positive recurrences 5
• Duration: Safety documented for up to 6 years of continuous use 4
• Reassessment: After 1 year of suppression, consider a trial off therapy to reassess recurrence frequency, as it often decreases over time 4

Alternative suppressive regimens: 4

• Valacyclovir 500 mg once daily (can increase to 1000 mg for very frequent recurrences)
• Famciclovir 250 mg twice daily

Renal Impairment Dosing

Evaluate renal function (creatinine clearance) before initiating therapy, especially in patients ≥80 years old, and adjust acyclovir dose based on creatinine clearance to prevent drug accumulation and neurotoxicity. 4, 2

Immunocompromised Patients

Immunocompromised patients require higher doses and longer treatment duration: 4, 2

• Oral therapy: Acyclovir 400 mg orally 3–5 times daily until complete resolution 4, 2
• Severe or extensive disease: Acyclovir 5–10 mg/kg IV every 8 hours for 5–7 days or until clinical improvement, then switch to oral therapy 2
• Acyclovir resistance: Occurs in ~7% of immunocompromised patients (vs. <0.5% in immunocompetent hosts); treat resistant HSV with foscarnet 40 mg/kg IV three times daily 4, 2

Alternative Oral Antivirals

While the question asks specifically about acyclovir, valacyclovir and famciclovir offer superior convenience with comparable efficacy: 1, 4

• Valacyclovir 2 g twice daily for 1 day (single-day therapy, highest convenience) 1, 4
• Famciclovir 1500 mg single dose (reduces healing time from 6.2 to 4.4 days) 1, 4

Important Clinical Caveats

Topical Therapy Limitations

Topical acyclovir provides only modest benefit and is substantially less effective than oral therapy; it should not be used as primary treatment. 4, 6, 7

Transmission Risk

• Patients remain contagious until all lesions are fully crusted 4
• Avoid direct contact (kissing, sharing utensils) while lesions are present 1, 4
• Asymptomatic viral shedding can occur even without visible lesions, so zero transmission risk does not exist even after healing 4

Patient Counseling

• Acyclovir neither eradicates latent virus nor affects subsequent recurrence risk after discontinuation 1
• Identify and avoid triggers: UV light exposure (use SPF ≥15 sunscreen), fever, stress, menstruation 4, 7
• Provide patients with a prescription to keep on hand for immediate self-initiation at first symptoms 4

Common Pitfalls to Avoid

• Starting treatment too late (>24 hours after lesion onset) 1, 4
• Using topical therapy when oral therapy is indicated 4, 6
• Failing to consider suppressive therapy in patients with ≥6 episodes/year 4
• Not adjusting dose for renal impairment in elderly patients 4